KPV vs Cartalax
Side-by-side comparison of KPV and Cartalax: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
KPV
Cartalax
KPV
KPV is a three-amino-acid peptide — Lysine-Proline-Valine — that makes up the C-terminal tail of alpha-MSH (alpha-melanocyte-stimulating hormone). With a molecular weight of only 342.4 Da, it is one of the smallest…
Lowest listed price: $34.99 across 6 listings
Full KPV profileCartalax
Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "cartilage bioregulator" intended to…
Lowest listed price: $58.85 across 3 listings
Full Cartalax profileSide-by-side comparison
| Attribute | KPV | Cartalax |
|---|---|---|
| Category | Recovery | Recovery |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | KPV's mechanism of action has been worked out in detail over the past 20 years, and it is unusual enough to be worth understanding if you are using this compound. Unlike most peptides, KPV does not primarily act through classical G-protein-coupled receptors on… | Mechanism of Action Cartalax's proposed mechanism is the Khavinson short-peptide framework applied to cartilage: passive membrane permeation, nuclear import, and sequence-selective chromatin modulation producing chondrocyte-favourable transcriptional shifts.… |
| Half-Life | Not measured: FDA's 2026 review found no pharmacokinetic studies of KPV in animals or people | No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured. |
| Typical Dose Range | 500 mcg-2 mg per dose (standard); up to 5 mg daily in advanced protocols | 20 mg oral/sublingual once daily for 10 days; 60-90 day washout |
| Dosing Frequency | Once daily subcutaneous or oral | Once daily |
| Administration | Subcutaneous, Oral, Topical | — |
| Side Effects | KPV's side effect profile, based on the published literature and the research-peptide community's accumulated experience, is notable primarily for what is NOT reported. Across preclinical studies, no serious adverse events have been attributed to KPV. That… | Side Effects and Safety Cartalax has been used in Russian clinical settings for roughly 20 years with a sparse adverse-event literature — reassuring in direction, insufficient for confident pharmacovigilance. Reported short-term adverse effects -… |
| Molecular Weight | 342.43 g/mol | 333.29 g/mol |
| Common Vial Sizes | 5mg, 10mg | — |
Price History
4 data points- OF
- BM
- Half Nattys
- Ion Peptide
- BHG Labs
Price History
3 data points- Ion Peptide
- Disguised Alpha
- LB
KPV: potential benefits
- Potent anti-inflammatory effects
- Gut healing and barrier repair
- Antimicrobial properties
- Skin wound healing support
- Potential anti-cancer properties (anti-angiogenic in tumors)
Cartalax: potential benefits
- Joint and cartilage repair support
- Connective tissue maintenance
- Anti-aging effects on musculoskeletal system
- Improved joint mobility
Frequently asked
What's the difference between KPV and Cartalax?
KPV is a recovery that kpv's mechanism of action has been worked out in detail over the past 20 years, and it is unusual enough to be worth understanding if you are using this compound. unlike most…. Cartalax is a recovery that mechanism of action cartalax's proposed mechanism is the khavinson short-peptide framework applied to cartilage: passive membrane permeation, nuclear import, and sequence-selective…. The two differ in mechanism, half-life (Not measured: FDA's 2026 review found no pharmacokinetic studies of KPV in animals or people vs No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured.), and typical dose range.
Which has the longer half-life, KPV or Cartalax?
KPV has a half-life of Not measured: FDA's 2026 review found no pharmacokinetic studies of KPV in animals or people. Cartalax has a half-life of No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, KPV or Cartalax?
Lowest listed price on BodyHackGuide: KPV from $34.99, Cartalax from $58.85. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack KPV and Cartalax?
Stacking depends on mechanism overlap, safety profile, and goals. KPV and Cartalax should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy KPV or Cartalax
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.